Uveitis Market By 2024
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
P e r s i s t e n c e M a r k e t R e s e a r c h<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Immunosuppressants<br />
Monoclonal antibodies<br />
Cycloplegic agents<br />
Antibodies<br />
Antivirals<br />
Antifungals<br />
Analgesics<br />
Corticosteroids will remain the largest segment, followed by antibiotics and monoclonal<br />
antibodies. While corticosteroids segment is foreseen to account for a dominant market share of<br />
over 21% in <strong>2024</strong>, antibiotics segment is expected to witness the fastest growth at a CAGR of<br />
8% – reaching beyond US$ 146 Mn over 2016-<strong>2024</strong>. Monoclonal antibodies segment will also<br />
exhibit healthy growth at a CAGR of 7%, reaching revenues worth US$ 142.7 Mn by the end of<br />
<strong>2024</strong>.<br />
Segmentation by disease type:<br />
Anterior uveitis<br />
Posterior uveitis<br />
Intermediate uveitis<br />
Panuveitis<br />
Anterior uveitis segment will continue to dominate. Through <strong>2024</strong>, this segment will capture<br />
around 60% value share, representing a value of over US$ 500 Mn. Posterior uveitis is also<br />
estimated for a considerable market value share of over 23% in <strong>2024</strong>. Attributed to increased<br />
prevalence of TB in intermediate uveitis, the intermediate uveitis will possibly be the second<br />
fastest growing segment over the forecast period.<br />
Segmentation by cause:<br />
Infectious<br />
Non-infectious<br />
On the basis of cause, infectious uveitis will remain the larger segment with over 87% share by<br />
<strong>2024</strong> end but non-infectious uveitis is predicted to witness a higher CAGR of 7.4% during the<br />
eight-year period.<br />
Segmentation by distribution channel:<br />
Hospital pharmacies<br />
Retail pharmacies<br />
Online pharmacies<br />
Drug stores<br />
<strong>By</strong> distribution channel, hospital pharmacies segment will account for over 46% revenue share in<br />
<strong>2024</strong>, whereas retail pharmacies segment is likely to capture around 30% share. Online<br />
pharmacies and drug stores segments will also witness healthy growth at over 6% CAGR during<br />
the aforementioned period.<br />
Segmentation by region:<br />
The report provides regional analysis that examines the global market classifying it into five key<br />
regions.<br />
<br />
<br />
<br />
North America<br />
Latin America<br />
Europe<br />
North America Wound Debridement Products <strong>Market</strong> by <strong>2024</strong>